Search - tctmd.com

Displaying 121 - 140 of 502

Sort: Relevancy | Date

News Daily News

Analysis Supports Short DAPT Followed by P2Y12 Inhibitor Monotherapy After DES PCI

L.A. McKeown

August 10, 2020

News Daily News

NSAIDs Boost CV, Bleeding Risks in Post-MI Patients

Todd Neale

July 28, 2020

News Daily News

STEMI Spectrum in COVID-19 Captured by Multinational Case Series

Caitlin E. Cox

July 08, 2020

News Daily News

Polymer-Free DES Hold No Long-term Advantage: ISAR-TEST-5

Michael O'Riordan

July 07, 2020

News Daily News

PCI or Not, Post-ACS Bleeding Is Tied to Mortality

Todd Neale

July 06, 2020

News Daily News

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

Michael O'Riordan

May 05, 2020

News Daily News

Clopidogrel Holds Advantage in Older NTSE ACS Patients: POPular AGE Published

Michael O'Riordan

April 27, 2020

News Features

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

Michael O'Riordan

April 07, 2020

News Conference News ACC 2020

TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients

Todd Neale

March 31, 2020

Presentation ACC 2020

Ticagrelor With or Without Aspirin in Acute Coronary Syndrome After PCI: Randomized Evaluation Of Ticagrelor Monotherapy After 3- month Dual-antiplatelet Therapy In Acute Coronary Syndrome The TICO trial

Presenter: Yangsoo Jang

March 30, 2020

News Conference News ACC 2020

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

Yael L. Maxwell

March 30, 2020

News Daily News

Better Adherence to Guideline Advice Pays Off After Acute MI

Yael L. Maxwell

March 11, 2020

News Daily News

Potent Antithrombotic Therapy Cuts Spontaneous MI After PCI for ACS

Yael L. Maxwell

March 10, 2020

News Daily News

New Meta-analysis Supports NOAC Plus P2Y12 Inhibitor for PCI in A-fib

Shelley Wood

February 28, 2020

News Conference News CRT 2020

PCI-Related MIs Not Linked to Mortality at 1 Year: Onyx ONE

Michael O'Riordan

February 25, 2020

News Conference News CRT 2020

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

L.A. McKeown

February 25, 2020

News Daily News

Early CVD Readmissions and Mortality Patterns Differ in Canada and the US

Yael L. Maxwell

February 18, 2020

Presentation JIM 2020

Clinical Crossroads On Optimal Antithrombotic Therapy In Patients Treated With Pci Intravenous Antiplatelet Therapy In High Risk Acs

Presenter: Dominick Angiolillo

February 13, 2020

Presentation JIM 2020

Intravenous antiplatelet therapy in high risk ACS:GPIIb/IIIa inhibitors are still a good option

Presenter: Marco Ferlini

February 13, 2020

News Daily News

Outcome Differences Between Men and Women With PAD: EUCLID Insights

L.A. McKeown

February 11, 2020

Advertisement

Analysis Supports Short DAPT Followed by P2Y12 Inhibitor Monotherapy After DES PCI

NSAIDs Boost CV, Bleeding Risks in Post-MI Patients

STEMI Spectrum in COVID-19 Captured by Multinational Case Series

Polymer-Free DES Hold No Long-term Advantage: ISAR-TEST-5

PCI or Not, Post-ACS Bleeding Is Tied to Mortality

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

Clopidogrel Holds Advantage in Older NTSE ACS Patients: POPular AGE Published

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients

Ticagrelor With or Without Aspirin in Acute Coronary Syndrome After PCI: Randomized Evaluation Of Ticagrelor Monotherapy After 3- month Dual-antiplatelet Therapy In Acute Coronary Syndrome The TICO trial

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

Better Adherence to Guideline Advice Pays Off After Acute MI

Potent Antithrombotic Therapy Cuts Spontaneous MI After PCI for ACS

New Meta-analysis Supports NOAC Plus P2Y12 Inhibitor for PCI in A-fib

PCI-Related MIs Not Linked to Mortality at 1 Year: Onyx ONE

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

Early CVD Readmissions and Mortality Patterns Differ in Canada and the US

Clinical Crossroads On Optimal Antithrombotic Therapy In Patients Treated With Pci Intravenous Antiplatelet Therapy In High Risk Acs

Intravenous antiplatelet therapy in high risk ACS:GPIIb/IIIa inhibitors are still a good option

Outcome Differences Between Men and Women With PAD: EUCLID Insights

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content